Neogenomics (NEO) Gross Profit (2010 - 2026)

Neogenomics (NEO) has 17 years of Gross Profit data on file, last reported at $91.9 million in Q2 2026.

• Quarterly Gross Profit rose 18.92% year-over-year to $91.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $336.5 million (up 11.2% YoY) and the FY2025 annual result came in at $314.3 million, up 8.34% from the prior year.
• Gross Profit rose to $91.9 million in Q2 2026, from $80.9 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $91.9 million in Q2 2026 to a low of $38.2 million in Q1 2022.
• A 5-year average of $67.2 million and a median of $70.0 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit fell 17.07% — and 2023, when it surged 43.37%.
• Tracing NEO's Gross Profit over 5 years: stood at $56.8 million in 2022, then rose by 18.94% to $67.6 million in 2023, then gained by 14.31% to $77.3 million in 2024, then advanced by 7.88% to $83.3 million in 2025, then advanced by 10.24% to $91.9 million in 2026.
• The last three Gross Profit figures came in at $91.9 million (Q2 2026), $80.9 million (Q1 2026), and $83.3 million (Q4 2025), per Business Quant data.